Press release
Neurofibromatosis Therapeutics Pipeline Analysis Report 2018: Clinical Trials & Results, Patents, Designations, Collaborations, and Other Developments
The study analyzed that the Neurofibromatosis therapeutics pipeline comprises of approximately 25 therapeutic candidates in different stages of development.Request to get the Sample Report@ https://www.psmarketresearch.com/market-analysis/neurofibromatoses-therapeutics-pipeline-analysis/report-sample
Majority of the pipeline drug candidates are being developed to be administered by oral route. Celldex Therapeutics Inc. and Merck Co. Inc. are in the process of developing a monoclonal antibody drug candidate, CDX0158, and Pembrolizumab respectively for the treatment of NF. Lixte Biotechnology Holdings Inc. is in the process of developing two drug candidates, in the Pre-Clinical stage of development for the treatment of neurofibromatosis (NF). In September 2016, the USFDA granted Orphan Drug Designation to BXCL101, a drug candidate of BioXcel Therapeutics Inc. for the treatment of NF type 2.
Since there is no treatment available for NF, the growing medical needs of the people suffering from the disease are driving its therapeutics pipeline growth. High rate of recurrence/progression of the disease and poor long-term benefit of surgery can be viewed as a limitation of this treatment option.
Explore Full Report Description At@ https://www.psmarketresearch.com/market-analysis/neurofibromatoses-therapeutics-pipeline-analysis
The drugs being developed by the different pharmaceutical companies demonstrated positive clinical trial results which in-turn increasing their further development. For instance, In June 2014, Array BioPharma Inc. announced positive results of Phase I/II, combination of binimetinib and LEE011. Selumetinib being developed by the AstraZeneca plc. And it met primary endpoint as confirmed partial responses (tumor volume decreases from baseline of ≥20%) in 17 of the 24 children (71%) in Phase I study.
Some of the key players developing drugs for the treatment of neurofibromatosis include Novartis AG, AstraZeneca Plc, Pfizer Inc., GlaxoSmithKline plc, Merck & Co. Inc, BioXcel Therapeutics, Inc.
About P&S Intelligence
P&S Intelligence, a brand of P&S Market Research, is a provider of market research and consulting services catering to the market information needs of burgeoning industries across the world. Providing the plinth of market intelligence, P&S as an enterprising research and consulting company, believes in providing thorough landscape analyses on the ever-changing market scenario, to empower companies to make informed decisions and base their business strategies with astuteness.
P&S Intelligence
347, 5th Ave. #1402
New York City, NY - 10016
Toll-free: +1-888-778-7886 (USA/Canada)
Email: enquiry@psmarketresearch.com
Web: https://www.psmarketresearch.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Neurofibromatosis Therapeutics Pipeline Analysis Report 2018: Clinical Trials & Results, Patents, Designations, Collaborations, and Other Developments here
News-ID: 1147874 • Views: …
More Releases from P&S Intelligence

U.S. ESG Investments Market Set to Skyrocket: $16 Trillion by 2032
According to the latest market research study published by P&S Intelligence, the U.S. Environmental, Social, and Governance (ESG) investments market is experiencing a significant surge, with projections indicating an increase from $6.5 trillion in 2024 to an estimated $16.0 trillion by 2032. This represents a robust compound annual growth rate (CAGR) of 12.1% over the forecast period.
According to a comprehensive analysis by P&S Intelligence, the market's expansion is driven…

Facility Management in the U.K. Booms with 14.1% CAGR as Demand Soars Across Sec …
According to the latest market research study published by P&S Intelligence, the U.K. facility management market is poised for significant growth, with projected revenues reaching USD 2,743.3 million in 2024 and expected to soar to USD 6,038.4 million by 2030, reflecting a robust CAGR of 14.1% during the forecast period.
This expansion is fueled by a surge in demand across both public and private sectors. According to the RICS U.K.…

Point-of-Sale Software Market in the U.S. Set to Grow by 9.7% CAGR, Boosted by O …
According to the latest market research study published by P&S Intelligence, the U.S. point-of-sale (POS) software market, valued at USD 4.7 billion in 2024, is poised for significant growth over the coming years, with projections estimating it will reach USD 9.8 billion by 2032, expanding at a compound annual growth rate (CAGR) of 9.7%. This growth is attributed to rapid technological advancements, a surge in mobile and cloud-based POS systems,…

Competitive Landscape of the Industrial Starches Market: Key Players, Trends, an …
According to the latest market research study published by P&S Intelligence, the global industrial starches market is poised for significant growth, with a projected increase from USD 110.3 billion in 2024 to USD 169.9 billion by 2030, at a robust compound annual growth rate (CAGR) of 7.5%. Industrial starches play a crucial role in diverse sectors, including food, pharmaceuticals, and paper, driven by their unique properties such as stabilizing, thickening,…
More Releases for Therapeutics
Adrenomyeloneuropathy Market: Epidemiology, Therapies, Companies, DelveInsight | …
Adrenomyeloneuropathy emerging therapies are expected to boost the Adrenomyeloneuropathy Market in the upcoming years.
DelveInsight has launched a new report on "Adrenomyeloneuropathy - Market Insights, Epidemiology, and Market Forecast-2034" that delivers an in-depth understanding of the Adrenomyeloneuropathy, historical and forecasted epidemiology as well as the Adrenomyeloneuropathy market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Discover about the Adrenomyeloneuropathy market report @ https://www.delveinsight.com/report-store/adrenomyeloneuropathy-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr
Some of the…
Pompe Disease Market: Epidemiology, Therapies, Companies, DelveInsight | Genzyme …
Pompe Disease emerging therapies, such as MYOZYME (alglucosidase alfa), LUMIZYME, AAV2/8-LSPhGAA, Avalglucosidase alfa, and others, are expected to boost the Pompe Disease Market in the upcoming years.
DelveInsight has launched a new report on "Pompe Disease - Market Insights, Epidemiology, and Market Forecast-2034" that delivers an in-depth understanding of the Pompe Disease, historical and forecasted epidemiology as well as the Pompe Disease market trends in the United States, EU5 (Germany, Spain,…
Dark Genome Therapeutics Market Deep Research Report with Forecast to 2032 | myN …
The qualitative latest Research report (2025-2032) on the Dark Genome Therapeutics Market by Coherent Market Insights Provides a deep dive into key market trends, drivers, challenges, and the competitive landscape. It analyzes market size, revenue, production, and CAGR using validated methodologies to ensure precision. The report highlights tech innovation, pricing trends, consumer behavior, and investment potential - empowering businesses to make informed, strategic moves.
Request a Sample Copy: https://www.coherentmarketresearch.com/samplepages/133611
Focused on growth…
Hodgkin's lymphoma Therapeutics Market Size Report 2032 | Affimed Therapeutics, …
DelveInsight's "Hodgkin's Lymphoma Market Insights, Epidemiology, and Market Forecast - 2032" report delivers an in-depth understanding of the Hodgkin's Lymphoma, historical and forecasted epidemiology as well as the Hodgkin's Lymphoma market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United kingdom and Japan.
Discover Key Insights into the Hodgkin's lymphoma Market with DelveInsight's In-Depth Report @ Hodgkin's lymphoma Market Size- https://www.delveinsight.com/sample-request/hodgkins-lymphoma-hl-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Key Takeaways from the Hodgkin's…
CRISPR Therapies Pipeline 2024 | Intellia Therapeutics, CRISPR therapeutics, Rep …
DelveInsight's, "CRISPR Therapies Pipeline Insight 2024" report provides comprehensive insights about 25+ CRISPR Therapies Companies and 30+ pipeline drugs in CRISPR Therapies pipeline landscape. It covers the CRISPR Therapies pipeline drug profiles, including clinical and nonclinical stage products. It also covers the CRISPR Therapies therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive CRISPR Therapies pipeline products in this space.
Key Takeaways from…
Digital Therapeutics Market, Digital Therapeutics Market Size, Digital Therapeut …
The global digital therapeutics market is expected to reach US$ 8,941.1 Mn by 2025 from US$ 1,993.2 Mn in 2017. The market is estimated to grow with a CAGR of 20.8% during the forecast period from 2018 to 2025.
North America is the largest geographic market and it is expected to be the largest revenue generator during the forecast period, whereas the market is expected to witness growth at a significant…